Latest Indian Price Caps Face Early Industry Dissent
This article was originally published in Scrip
Executive Summary
The Indian regulator's latest move capping prices of over 100 formulations appears to be facing some dissent with industry moving a review application over what it claims are certain untenable requirements especially for drugs already being sold below the ceiling price.